BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16995869)

  • 1. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.
    Picard N; Prémaud A; Rousseau A; Le Meur Y; Marquet P
    Br J Clin Pharmacol; 2006 Oct; 62(4):477-84. PubMed ID: 16995869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment.
    Büchler M; Lebranchu Y; Bénéton M; Le Meur Y; Heng AE; Westeel PF; le Guellec C; Libert F; Hary L; Marquet P; Paintaud G
    Clin Pharmacol Ther; 2005 Jul; 78(1):34-42. PubMed ID: 16003290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM; Ekberg H; Mamelok RD; Oppenheimer F; Sánchez-Plumed J; Gentil MA; Hernandez D; Kuypers DR; Brunet M
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics.
    Braun F; Schöcklmann H; Ziegler E; Kunzendorf U; Armstrong VW; Renders L
    Clin Pharmacol Ther; 2009 Oct; 86(4):411-5. PubMed ID: 19606088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.
    Djebli N; Picard N; Rérolle JP; Le Meur Y; Marquet P
    Pharmacogenet Genomics; 2007 May; 17(5):321-30. PubMed ID: 17429314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.
    Atcheson BA; Taylor PJ; Mudge DW; Johnson DW; Hawley CM; Campbell SB; Isbel NM; Pillans PI; Tett SE
    Br J Clin Pharmacol; 2005 Mar; 59(3):271-80. PubMed ID: 15752372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.
    Pescovitz MD; Vincenti F; Hart M; Melton L; Whelchel J; Mulgaonkar S; McKay D; Leung M; Calleja E; Bouw MR
    Br J Clin Pharmacol; 2007 Dec; 64(6):758-71. PubMed ID: 17555465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen.
    Greanya ED; Poulin E; Partovi N; Shapiro RJ; Al-Khatib M; Ensom MH
    Am J Health Syst Pharm; 2012 Jan; 69(2):134-42. PubMed ID: 22215359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
    Neumann I; Fuhrmann H; Kanzler M; Fang IF; Jaeger A; Graf H; Bayer P; Kovarik J
    Expert Opin Pharmacother; 2008 Apr; 9(6):879-86. PubMed ID: 18377332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.
    Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA
    Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients.
    González-Roncero FM; Govantes MA; Chaves VC; Palomo PP; Serra MB
    Transplant Proc; 2007 Sep; 39(7):2176-8. PubMed ID: 17889129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ; Nawrocki A; Pescovitz MD; Bouw R; Shaw LM
    Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.